Pharmacotherapy for Alcohol Dependence: Anticraving Medications for Relapse Prevention
Yonsei Medical Journal
;
: 167-178, 2006.
Artículo
en Inglés
| WPRIM
| ID: wpr-113995
ABSTRACT
Alcohol dependence is a chronic disorder that results from a variety of genetic, psychosocial, and environmental factors. Relapse prevention for alcohol dependence has traditionally involved psychosocial and psychotherapeutic interventions. Pharmacotherapy, however, in conjunction with behavioral therapy, is generating interest as another modality to prevent relapse and enhance abstinence. Naltrexone and acamprosate are at the forefront of the currently available pharmacological options. Naltrexone is an opioid receptor antagonist and is thought to reduce the rewarding effect of alcohol. Acamprosate normalizes the dysregulation of N-methyl-D-aspartate (NMDA)-mediated glutamatergic excitation that occurs in alcohol withdrawal and early abstinence.These different mechanisms of action and different target neurotransmitter systems may endow the two drugs with efficacy for different aspects of alcohol use behavior. Since not all patients seem to benefit from naltrexone and acamprosate, there are ongoing efforts to improve the treatment outcomes by examining the advantages of combined pharmacotherapy and exploring the variables that might predict the response of the medications. In addition, novel medications are being investigated to assess their efficacy in preventing relapse and increasing abstinence.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Polimorfismo Genético
/
Recurrencia
/
Taurina
/
N-Metilaspartato
/
Receptores Opioides
/
Receptores Opioides mu
/
Disulfiram
/
Disuasivos de Alcohol
/
Alcoholismo
/
Ácido gamma-Aminobutírico
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Yonsei Medical Journal
Año:
2006
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS